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Abstract
Background: Male breast cancer is a comparatively rare disease, and simultaneous bilateral male
breast cancer is considered to be an extremely rare event. Risk factors are said to be genetic
factors and hormonal abnormalities due to obesity or testicular diseases.
Case presentation: The patient was a 47-year-old Japanese male. His family had no history of
female breast cancer. This patient also had hypospadias and hormonal examination indicated the
presence of primary testicular potential hypogonadism, and these hormonal abnormalities seemed
to be present since childhood or the fetal period. The bilateral breast cancer developed in this man
at a comparatively young age, and histopathological studies of multiple sections showed that there
was almost no normal epithelial cell in the ducts, while the ducts were almost completely filled with
breast cancer cells.
Conclusion: It is thought that male breast cancer is caused by an imbalance between estrogen and
testosterone. We cannot rule out the possibility that the breast cancer developed due to the effect
of the slight elevation of estrogen over a long period of time, but the actual causative factors in this
patient were unable to be definitively identified. In the future, we hope to further elucidate the
causes of male breast cancer.
Background
Male breast cancer (MBC) is a comparatively rare disease,
accounting for 1% or less of all male cancers and only
about 1% of all breast cancers [1-4]. In addition, bilateral
breast cancer accounts for only 1.5–2% of MBC, and
simultaneous cancers is extremely rare [5-8]. The consen-
sus is that MBC is caused by an imbalance between estro-
gen and testosterone [4,9]. Various risk factors have been
proposed for MBC, including BRCA2 gene anomalies
[10], Klinefelter's syndrome [11], a genetic background
such as a familial history of breast cancer, hormonal
abnormalities due to obesity or testicular disease (cryp-
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radiation [1-4,9]. Here, we report a case of simultaneous
bilateral breast cancer diagnosed in a Japanese male. This
case is discussed in relation to the published literature.
Case presentation
A 47-year-old Japanese male who worked for a food com-
pany, presented with complaint of a bloody discharge
from the left nipple. This patient also had hypospadias, a
condition that also existed in one male relative. There was
no familial history of breast cancer. The patient had
undergone plastic surgery for the hypospadias two times
at the age of 4–5 years. Then, at the age of 20–21 years the
patient underwent four more plastic surgery operations
for the hypospadias. The patient was male in appearance.
He has male sterility and had no history of trauma to the
external genitalia or mumps. As the history of the present
disease, the patient noticed a bloody discharge from the
left nipple and thus came to the authors' hospital for
examination. The body height was 175 cm, the body
weight was 80 kg, and with a BMI of 26.1 the patient
showed a slight tendency to obesity. Examination yielded
local findings of a bloody discharge from a single duct of
each of the bilateral nipples. Palpation did not detect any
clear mass in either of the breasts or their areolas. The axil-
lary lymph nodes were not palpated. Mammography
revealed scattered microcalcifications in the left breast
(Figure 1). There were no abnormal findings for the right
breast. Ultrasonography showed a hypo-echoic lesion of 3
mm in diameter in C region of the left breast (Figure 2),
and the right breast showed duct dilatation in C region.
Fine-needle aspiration cytology showed class V for both
the left and right breasts, and smear cytology also showed
class V for both breasts.
Blood tests showed no abnormalities. Hormone tests gave
the following results: LH 25.5 mIU/ml (normal range:
1.1~8.8), FSH 33.6 mIU/ml (1.8~13.6), PRL 18.8 ng/ml
(3.6~12.8), E1 96.2 pg/ml (10~90), E2 28.1 pg/ml
(20~60.1), E3 ≤ 5 pg/ml (≤ 5), testosterone 4.11 ng/ml
(2.7–11) and free-testosterone 9.1 pg/ml (6.9–18.4).
Thus, LH and FSH were high, and PRL was slightly ele-
vated. On the other hand, E1 was slightly elevated,
whereas E2, E3, testosterone and free testosterone were
normal. In the LHRH loading test, LH and FSH increased
normally, but testosterone and estrogen showed poor
responses. In the hCG loading test (briefly, the measure-
ment of testosterone was performed about 2 h after load-
ing of hCG 10000 IU/body), testosterone showed a
baseline (preloading) value of 4.82 ng/ml and then
increased only slightly to 7.41 ng/ml after loading. This
result indicated the presence of primary potential hypog-
onadism. In addition, a chromosomal study showed a
normal male karyotype of 46XY. Considering the history
of hypospadias, the patient was referred to the Urology
Department for detailed tests relating to male sexual func-
tion insufficiency, sexual differentiation abnormality. The
Urology Department found the patient to have a normal
male form in terms of the outward appearance, head of
hair, hair growth in the inguinal region, but at the penile-
scrotal angle there was scarring from the surgery for the
hypospadias. Palpation revealed an elastic, soft, testicle-
like portion in the bilateral scrota. Ultrasonography
showed that both testes had undergone overall degenera-
tion to multilocular cysts, and there was overall enlarge-
ment of the testes (Figure 3). Pelvic MRI examination
showed the bilateral scrota to be filled with a water-den-
sity mass, and there were no clear findings characteristic of
testes.
On the basis of the above findings, a diagnosis of male
bilateral breast cancer accompanied by male potential
hypogonadism was made. Simple mastectomy was per-
formed on both breasts.
Mammography revealed scattered microcalcifications in the left breastFigu  1
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atypical cells in the duct of the left breast, and that was
accompanied by partial necrosis. A diagnosis of noninva-
sive ductal carcinoma was made (Figure 4). In addition,
immunohistochemical staining of the left breast showed
the tumor to be estrogen receptor (ER) (+ve), progester-
one receptor (PgR) (+ve) and HER2/neu(-ve). In the right
breast, most of the atypical cell proliferation was in the
duct, but there was also some invasion of the stroma by
atypical cells, leading to a diagnosis of invasive ductal car-
cinoma, solid-tubular type (partial papillotubular type).
As in the left breast, there was partial necrosis (Figure 5),
and the immunohistochemical staining results were again
ER (+ve), PgR (+ve) and HER2/neu (-ve). In addition,
inspection of multiple sections from the bilateral breasts
found almost no normal epithelial cells in the ducts, and
the insides of the ducts were almost totally filled with can-
cerous issue.
Postoperatively, endocrine therapy consisting of
tamoxifen 20 mg per day is being administered, and as of
this writing there has been no evidence of recurrence of
the malignancy.
Discussion
MBC is considered to be a rare disease, and bilateral,
simultaneous MBC is extremely rare [1-4]. MBC is said to
be more common in elderly patients compared with the
disease in females [9]. It has been reported that the char-
acteristics of MBC are similar to those of postmenopausal
female breast cancer [3], but there are also reports that
hormonal receptor studies and studies of the therapeutic
efficacy of aromatase inhibitors indicate MBC to differ
from female breast cancer [12-15]. Various risk factors
have been pointed out for MBC, including BRCA2 gene
anomalies [10], Klinefelter's syndrome [11], a genetic
background such as a familial history of breast cancer,
hormonal abnormalities due to obesity or testicular dis-
ease (cryptorchidism, mumps, orchitis, orchiectomy),
exposure to radiation [1-4]. With regard to hormonal
abnormalities, it has been reported that MBC is caused by
an imbalance between estrogen and testosterone [4,9].
Ultrasonography showed a hypo-echoic legion of 3 mm in diameter in C region of the left breastFigure 2
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were administered an estrogen for a long period of time
[1], and estrogen is thought to play an important role in
the development of MBC since the plasma concentration
of this hormone is higher in MBC patients than in normal
males [1-3,9]. It is said that the production, metabolism
and bioavailability of estrogen are enhanced in the subcu-
taneous tissues of obese males as a result of activation of
aromatase, a decrease in sex-hormone-binding globulin
(SHBG) and for these reasons obesity has been reported as
a risk factor for MBC [2]. On the other hand, with regard
to testosterone, castration for the purpose of gender trans-
formation or prostate gland therapy is said to increase the
risk of MBC, while testicular dysfunction due to mumps
or cryptorchidism alters the levels of estrogens, androgens
and gonadotropins and is also thought to increase the risk
of MBC [3]. Prolactin is involved in the differentiation
and development of normal breast tissue, and there have
Ultrasonography showed that both testes had undergone overall degeneration to multilocular cysts, and there was overall enlargement of the testesFigur  3
Ultrasonography showed that both testes had undergone overall degeneration to multilocular cysts, and there was overall 
enlargement of the testes.
Carcinoma cells in a large lactiferous duct of the subareolar region (A)(×20)Figure 4
Carcinoma cells in a large lactiferous duct of the subareolar region (A)(×20). Noninvasive ductal carcinoma forming cribriform 
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pituitary tumor, especially when accompanied by hyper-
prolactinemia [6,7]. Also, because administration of prol-
actin has been shown to cause breast cancer in animal
studies, this hormone is thought to be strongly involved
in the development of this malignancy [16]. However,
prolactin is produced in an autocrine and/or paracrine
manner by breast cancer cells and normal breast cells, and
it is said that its activity is expressed only at the cellular
level. Thus, it has been judged that it does not exert any
influence on prolactin production by the pituitary, and
that pituitary prolactin production is not involved in the
development of breast cancer [17].
BRCA2 testing was not performed on our present patient.
However, since there was no familial history of breast can-
cer, it can be surmised that the cause of the disease was the
hormonal disturbances rather than genetic factors. More-
over, the facts that this patient was rather young (47 years
old) to have this disease and that the disease was simulta-
neously bilateral point to the existence of high risk factors.
A chromosomal study showed the patient to have a nor-
mal male karyotype of 46XY, but he had complications of
hypospadias and male potential hypogonadism. Hypos-
padias is one of the most commonly occurring congenital
abnormalities, and one of its causes is thought to be hor-
monal abnormalities during the fetal stage [18]. In addi-
tion, although androgen gene and/or androgen receptor
gene anomalies might be thought to be involved [3], this
patient showed only a mild degree of abnormality of the
external sex organs and presented a normal male appear-
ance in terms of the body type, development of body hair.
Also, the fact that there was only a slight increase in the
testosterone level following a loading test provides further
evidence negating involvement of these two genetic
anomalies in this patient. However, there is a possibility
that the hypospadias was familial in nature, and thus we
cannot rule out the possible existence of other genetic
anomalies in the patient.
In an attempt to elucidate the causative mechanism of the
bilateral breast cancer in this Japanese male, we per-
formed various hormone tests. Imaging studies found
almost no normal testicular tissue, but in the hCG loading
test testosterone increased even if only slightly, and
although the hormone secretion function of the testes was
disturbed, the function can nevertheless be considered to
have been about half of normal. This suggests that a par-
tial Leydig cell function of cyst wall do exist. It can be sur-
mised that this was because stimulation by LH and FSH
due to feedback arising from the testicular potential
hypogonadism caused secretion of testosterone from tes-
tes and from adrenal glands and thus maintained a nor-
mal serum testosterone level.
In addition, since the patient showed a tendency to obes-
ity, the finding that the E1 level was slightly increased
even though the testosterone level was normal can be
thought to have been a result of estrogen production via
aromatase in the adipose cells. We did not measure the
level of SHBG, but it can be assumed that SHBG was
nearly normal since the level of free testosterone was nor-
mal. An SHBG abnormality would affect the estrogen
activity, but there was no striking evidence of such an
effect in this patient. There is doubt regarding whether a
Noninvasive ductal carcinoma, micropapillary and cribriform(A)(×20)Figure 5
Noninvasive ductal carcinoma, micropapillary and cribriform(A)(×20). Invasive ductal carcinoma with small coagulative necrosis 
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slight elevation of only E1 in men has any clinical signifi-
cance. Pathologically, the disease developed bilaterally in
this patient, and histopathological studies of multiple sec-
tions of the resected specimen found almost no normal
ductal tissue and almost entirely breast cancer cells. We
cannot exclude the possibility that the breast cancer in this
patient developed only due to these hormonal abnormal-
ities. Measurements were carried out three times at set
intervals, but each time the PRL level was slightly elevated.
As noted earlier, PRL has been ruled out as a cause of
breast cancer [17]. However, there have been reports of
bilateral MBC accompanied by hyperprolactinemia [6,7],
and in this light we cannot exclude the possibility that
PRL may indeed be somehow involved. In addition, there
have been reports that MBC clearly differs from postmen-
opausal female breast cancer, including recommendation
of use of a gonadotropin-releasing hormone analog to
interrupt the feedback from the pituitary that occurs at the
time of administration of an aromatase inhibitor as ther-
apy for breast cancer in males [12,13]. In the future, we
hope to further elucidate the causes of MBC.
Conclusion
Risk factors for male breast cancer are said to be genetic
factors, hormonal abnormalities. The Japanese male
patient reported here had developed bilateral breast can-
cer at a comparatively young age, and in the absence of a
familial history of breast cancer it was surmised that the
disease had been caused by hormonal abnormalities
rather than genetic factors. The patient has male potential
hypogonadism that was accompanied by hypospadia. The
possibility that the breast cancer developed due to the
effect of the slight elevation of estrogen over a long period
of time cannot be ruled out, but the actual causative fac-
tors in this patient were unable to be definitively identi-
fied. In the future, we hope to further elucidate the causes
of MBC.
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